Marcelo Vailati Negrao, MD, discusse safety outcomes with first-line olomorasib plus chemoimmunotherapy in LOXO-RAS-20001 and SUNRAY-01.
Marcelo, Vailati Negrao, MD
Advertisement
Articles by Marcelo, Vailati Negrao, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Investigating Novel Immunotherapy Targets in Metastatic RCC
4
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
5